Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental blood cancer drug trial halted early

NCT ID NCT05787496

First seen Feb 01, 2026 · Last updated Jun 18, 2026 · Updated 13 times

Summary

This early-stage trial tested a new drug called NC525 in 28 adults with advanced blood cancers (leukemia and related disorders) that had not responded to standard treatments. The main goals were to check the drug's safety and find the right dose. The study was stopped early, so results are limited, but the data may still help researchers understand how to treat these hard-to-manage cancers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • City of Hope

    Duarte, California, 91010, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri, 63110, United States

  • Weill Cornell Medicine

    New York, New York, 10022, United States

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia chronic myelomonocytic leukemia leukemia myelodysplastic syndrome Myelodysplastic Syndromes Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.